Global Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>GC</div>
CO -- USA Stock  

USD 3.39  0.02  0.59%

It looks like Guardant Health will be up for a correction faster as its share price went up 0.14% today to Global Cord's 2.22%As many rational traders are trying to avoid healthcare space, it makes sense to outline Global Cord Blood a little further and understand how it stands against Guardant Health and other similar entities. We are going to inspect some of the competitive aspects of both Global and Guardant.
Published over three weeks ago
View all stories for Global Cord | View All Stories
Will Global Cord (NYSE:CO) institutional investors shift to Guardant (NASDAQ:GH)?
By analyzing existing basic indicators between Global Cord and Guardant, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Guardant with a short position in Global Cord. Check out our pair correlation module for more information.

Let's begin by analyzing the assets. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Global Cord has an asset utilization ratio of 3.11 percent. This suggests that the company is making $0.0311 for each dollar of assets. An increasing asset utilization means that Global Cord Blood is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as Global or Guardant is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Global Cord's Liquidity

Global Cord financial leverage refers to using borrowed capital as a funding source to finance Global Cord Blood ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Global Cord financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Global Cord's total debt and its cash.

Correlation Between Global and Guardant Health

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Global Cord together with similar or unrelated positions with a negative correlation. For example, you can also add Guardant Health to your portfolio. If Guardant Health is not perfectly correlated to Global Cord it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Global Cord for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down. Please check pair correlation details between CO and GH for more information.

Purchase by Mccarthy Kent C of 161000 shares of Global Cord

Legal trades by Global Cord insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Global insider trading alert for perchase of warrant by Mccarthy Kent C, the corporate stakeholder, on 30th of August 2020. This event was filed by Global Cord Blood Corp with SEC on 2009-11-25. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Global Cord Indicators

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Lets now check Global Cord revenue. Based on the latest financial disclosure, Global Cord Blood reported 145.75 M of revenue. This is 98.09% lower than that of the Healthcare sector and 92.64% lower than that of the Diagnostics & Research industry. The revenue for all United States stocks is 98.46% higher than that of Global Cord. As for Guardant Health we see revenue of 257.59 M, which is 87.0% lower than that of the Diagnostics & Research

Sector
B
CO145.75 Million6.11
Sector1.98 Billion83.09
GH257.59 Million10.8

Another small slide for Global Cord

Treynor ratio is down to 1.13. It may entail a possible volatility slide. As of the 24th of August, Global Cord retains the Risk Adjusted Performance of 0.1998, market risk adjusted performance of 1.14, and Downside Deviation of 2.98. Global Cord technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Global Cord Blood, which can be compared to its competitors. Please check out Global Cord Blood jensen alpha, as well as the relationship between the potential upside and skewness to decide if Global Cord is priced fairly, providing market reflects its last-minute price of 3.52 per share. Given that Global Cord Blood has jensen alpha of 0.3916, we strongly advise you to confirm Global Cord Blood's regular market performance to make sure the company can sustain itself at a future point.

Whereas many of the other players in the diagnostics & research industry are either recovering or due for a correction, Global Cord may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 24th of August 2020, we see that Global Cord slowly supersedes the market. The company is undervalued with below average chance of distress within the next 24 months. Our latest 30 days buy-or-sell advice on the company is Strong Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Global Cord Blood. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com